Summit Corporation Share Price (SUMM)

151.00 -2.00 (-1.31%) delayed: 11:57PM BST
Bid price 149.00 Open price 153.00
Ask price 153.00 Prev close 151.00
High price 153.00 Spread 2.61%
Low price 149.50 Volume 245,392

Register now for FREE live Summit Corporation share prices, Summit Corporation stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Summit Corporation Level 2 Data, indepth research tools and investor commentary for Summit Corporation (SUMM) and other London Stock Exchange equities.

Summit Corporation Share Price Chart

Advanced Charts >>

Register now for FREE Summit Corporation share price charts

Summit Corporation Share Price Information

Name Summit Corporation Epic SUMM
Sector Pharmaceuticals & Biotechnology ISIN GB00BN40HZ01
Activites Summit plc (formerly VASTox plc) is a UK based drug discovery company with a major focus on developing new therapeutics from its iminosugar drug discovery platform. Summit believes iminosugars are the key to gaining access to several disease mechanisms where classical drugs have had little success, and thus offer a major opportunity for the discovery and development of new medicines. Carbohydrates (sugars) play critical roles in maintaining correct functioning of many normal processes in healthy individuals and errors in carbohydrate recognition or modification can lead to malfunction in cells resulting in disease. Iminosugars have the potential to mimic carbohydrates or to interact with processes which manipulate carbohydrates to modify activity or to correct aberrant function. Additionally, iminosugars, due to their sugar-like properties, have important effects when interacting with many other unexploited therapeutic targets. Index n/a

Summit Corporation Key Numbers

Latest Share Price (p) 151.00 Net Gearing (%) -2.43
Market Capitalisation (£m) 62.82 Gross Gearing (%) 28.19
Shares in issue (m) 41.06 Debt Ratio 0.00
P/E Ratio -102.69 Debt-to-Equity Ratio 0.00
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.39
Dividend Yield (%) 0.00 Price to book value 13.20
Dividend cover (x) 0.00 ROCE -1.46
Earning per share (p) -1.49 EPS Growth (%) 0.00
52 week high / low 154.50 / 6.25 DPS Growth (%) n/a

Summit Corporation Director Deals

Dec.Date Type Director Pos No. of Shares
30/07/2014 BUY Glyn Edwards CEO 30,000
26/07/2013 PLAC Glyn Edwards CEO 600,000
26/07/2013 PLAC Dr Frank Armstrong CH 50,000
26/07/2013 PLAC Barry Price NED 500,000
26/07/2013 PLAC Jim Mellon NED 20,000,000

More Summit Corporation Director Deals >>

Summit Corporation Company News

12:00 07/08/2014

Summit to Present at the Canaccord Genuity 34th...

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Summit to Present at the Canaccord Genuity 34th Annual Growth Conference Summit Corporation plc ('Summit' or the 'Company') SUMMIT TO...

09:10 30/07/2014

Director Deals - Summit Corporation PLC (SUMM)

Glyn Edwards, Chief Executive Officer, bought 30,000 shares in the company on the 29th July 2014 at a price of 104.50p. The Director now holds 233,333 shares. Story provided by Director deals data provided by

07:00 30/07/2014

Director/PDMR Shareholding

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Director/PDMR Shareholding Summit Corporation plc ('Summit' or 'the Company') DIRECTOR SHAREHOLDINGS Oxford, UK, 30 July 2014 -...

More Summit Corporation Company News >>

Register now for FREE Summit Corporation company news

Summit Corporation Share Price Discussions

1 months ago

Summit Corporation PLC (SUMM) Summit is an Oxford, UK based drug discovery company developing novel drug candidates to treat areas of high unmet medical need. Our strategy has evolved to focus on the development of two high-value clinical-stage programmes that target the fatal genetic disease...

more than 1 year ago

Summer Bonanza is upon us.......... (SUMM)

OK folks it's mid March and spring is upon us. Time to start looking ahead, the mkts have had a bit of a setback, is this the healthy correction that's been spoken about for so long or is it a buying opportunity on the road to new highs? Who knows, not me for sure, if I did I'd tell ya'll...

Register now for FREE Summit Corporation share price discussions